阅读说明：本技术 一种治疗新型冠状病毒感染的肺炎的方剂及其应用 (Prescription for treating pneumonia infected by novel coronavirus and application thereof ) 是由 葛又文 于 2020-02-06 设计创作，主要内容包括：本发明涉及中药组合物,具体公开了一种治疗新型冠状病毒感染的肺炎的方剂及其应用。所述方剂的原料包括如下重量份的中药材料：麻黄9份、炙甘草6份、杏仁9份、生石膏15-30份、桂枝9份、泽泻9份、猪苓9份、白术9份、茯苓15份、柴胡16份、黄芩6份、姜半夏9份、生姜9份、紫苑9份、冬花9份、射干9份、细辛6份、山药12份、枳实6份、陈皮6份、藿香9份。本发明结合新型冠状病毒(2019-nCoV)感染的肺炎症状表现,利用中药组方优化融合,共同施治。从目前多省多地不同年龄层次的确诊患者救治情况看,疗效确切,治疗有效率达到95.12％。(The invention relates to a traditional Chinese medicine composition, and particularly discloses a prescription for treating pneumonia caused by novel coronavirus infection and application thereof. The raw materials of the prescription comprise the following traditional Chinese medicine materials in parts by weight: 9 parts of ephedra, 6 parts of honey-fried licorice root, 9 parts of almond, 15-30 parts of gypsum, 9 parts of cassia twig, 9 parts of rhizoma alismatis, 9 parts of grifola, 9 parts of bighead atractylodes rhizome, 15 parts of poria cocos, 16 parts of radix bupleuri, 6 parts of scutellaria baicalensis, 9 parts of ginger processed pinellia tuber, 9 parts of ginger, 9 parts of aster, 9 parts of flos farae, 9 parts of blackberry lily, 6 parts of asarum, 12 parts of Chinese yam, 6 parts of immature bitter orange, 6 parts of dried orange peel and 9 parts of wrinkled gianthyssop herb. The invention combines the pneumonia symptom expression of the novel coronavirus (2019-nCoV) infection, optimizes and fuses the traditional Chinese medicine formula, and treats the pneumonia together. From the prior treatment conditions of patients with confirmed diagnosis at different ages, a plurality of provinces and a plurality of places, the curative effect is definite, and the effective rate of the treatment reaches 95.12 percent.)

1. A prescription for treating pneumonia infected by novel coronavirus is characterized in that the raw materials comprise the following traditional Chinese medicine materials in parts by weight:

8-10 parts of ephedra, 5-8 parts of honey-fried licorice root, 8-10 parts of almond, 15-30 parts of gypsum, 8-10 parts of cassia twig, 8-10 parts of rhizoma alismatis, 8-10 parts of polyporus umbellatus, 8-10 parts of bighead atractylodes rhizome, 15 parts of poria cocos, 15-18 parts of radix bupleuri, 5-8 parts of scutellaria baicalensis, 8-10 parts of ginger processed pinellia tuber, 8-10 parts of ginger, 8-10 parts of aster, 8-10 parts of flos farfarae, 8-10 parts of blackberry lily, 5-8 parts of asarum, 10-14 parts of Chinese yam, 5-8 parts of immature bitter orange, 5-8 parts of dried orange peel and 8-10 parts of wrinkled gianthys.

2. The prescription according to claim 1, wherein the raw materials comprise the following Chinese medicinal materials in parts by weight:

9 parts of ephedra, 6 parts of honey-fried licorice root, 9 parts of almond, 15-30 parts of gypsum, 9 parts of cassia twig, 9 parts of rhizoma alismatis, 9 parts of grifola, 9 parts of bighead atractylodes rhizome, 15 parts of poria cocos, 16 parts of radix bupleuri, 6 parts of scutellaria baicalensis, 9 parts of ginger processed pinellia tuber, 9 parts of ginger, 9 parts of aster, 9 parts of flos farae, 9 parts of blackberry lily, 6 parts of asarum, 12 parts of Chinese yam, 6 parts of immature bitter orange, 6 parts of dried orange peel and 9 parts of wrinkled gianthyssop herb.

3. The prescription according to claim 2, wherein the Chinese medicinal raw materials comprise the following Chinese medicinal materials in parts by weight:

9 parts of ephedra, 6 parts of honey-fried licorice root, 9 parts of almond, 15-30 parts of gypsum, 9 parts of cassia twig, 9 parts of rhizoma alismatis, 9 parts of grifola, 9 parts of bighead atractylodes rhizome, 15 parts of poria cocos, 16 parts of radix bupleuri, 6 parts of scutellaria baicalensis, 9 parts of ginger processed pinellia tuber, 9 parts of ginger, 9 parts of aster, 9 parts of flos farae, 9 parts of blackberry lily, 6 parts of asarum, 12 parts of Chinese yam, 6 parts of immature bitter orange, 6 parts of dried orange peel and 9 parts of wrinkled gianthyssop herb.

4. The formulation of any one of claims 1 to 3, in the form of a decoction.

5. A process for the preparation of a formulation as claimed in any one of claims 1 to 4, wherein the raw materials are decocted with water, wherein gypsum is first decocted and the other ingredients are then added and decocted.

6. Use of a formulation according to any one of claims 1 to 4 for the manufacture of a medicament having lung clearing and detoxifying effects.

7. Use of a formulation according to any one of claims 1 to 4 in the manufacture of a medicament for the treatment of pulmonary inflammatory diseases.

8. The use of claim 7, wherein the pneumonia is caused by a viral infection.

9. The use according to claim 8, wherein said viruses include, but are not limited to, novel coronavirus 2019-nCoV, respiratory syndrome coronavirus, and respiratory syncytial virus.

Technical Field

The invention relates to a traditional Chinese medicine composition, in particular to a prescription for treating pneumonia infected by novel coronavirus.

Background

2019A novel coronavirus, temporarily named 2019-nCoV coronavirus, is a new strain of coronavirus found in human in 2019. The symptoms of the virus are fever, hypodynamia, dry cough and gradual dyspnea, and severe patients show acute respiratory distress syndrome, septic shock, metabolic acidosis and blood coagulation dysfunction which are difficult to correct. The virus is confirmed to have a phenomenon of human transmission, the latent period is infectious, and no specific treatment method is provided for the diseases caused by the infectious latent period.

Disclosure of Invention

In order to solve the problems in the prior art, the invention aims to provide a prescription (lung-clearing and toxin-expelling decoction) for treating pneumonia infected by novel coronavirus and application thereof.

In order to realize the purpose of the invention, the technical scheme of the invention is as follows:

in a first aspect, the invention provides a prescription for treating pneumonia infected by a novel coronavirus, which comprises the following Chinese medicinal materials in parts by weight:

8-10 parts of ephedra, 5-8 parts of honey-fried licorice root, 8-10 parts of almond, 15-30 parts of gypsum, 8-10 parts of cassia twig, 8-10 parts of rhizoma alismatis, 8-10 parts of polyporus umbellatus, 8-10 parts of bighead atractylodes rhizome, 15 parts of poria cocos, 15-18 parts of radix bupleuri, 5-8 parts of scutellaria baicalensis, 8-10 parts of ginger processed pinellia tuber, 8-10 parts of ginger, 8-10 parts of aster, 8-10 parts of flos farfarae, 8-10 parts of blackberry lily, 5-8 parts of asarum, 10-14 parts of Chinese yam, 5-8 parts of immature bitter orange, 5-8 parts of dried orange peel and 8-10 parts of wrinkled gianthys.

Preferably, the raw materials of the prescription comprise the following traditional Chinese medicine materials in parts by weight: 9 parts of ephedra, 6 parts of honey-fried licorice root, 9 parts of almond, 15-30 parts of gypsum, 9 parts of cassia twig, 9 parts of rhizoma alismatis, 9 parts of grifola, 9 parts of bighead atractylodes rhizome, 15 parts of poria cocos, 16 parts of radix bupleuri, 6 parts of scutellaria baicalensis, 9 parts of ginger processed pinellia tuber, 9 parts of ginger, 9 parts of aster, 9 parts of flos farae, 9 parts of blackberry lily, 6 parts of asarum, 12 parts of Chinese yam, 6 parts of immature bitter orange, 6 parts of dried orange peel and 9 parts of wrinkled gianthyssop herb.

The prescription of the invention refers to the Shang Zhong Jing (treatise on exogenous febrile diseases) of the classic Han Dynasty of traditional Chinese medicine, and is prepared from ephedra, almond, licorice and gypsum decoction (short for Ma xing Shi Gao decoction, Shang Han Lun 63), Xiao Chaihu decoction (Shang Han Lun 96), Wu Ling san (Shang Han Lun 71) and blackberry lily and ephedra decoction (Jinkui Yao, lung atrophy, lung carbuncle and cough upper qi syndrome treatment seventh) by reducing and cutting. The Chinese yam, the immature bitter orange, the dried orange peel and the wrinkled giant hyssop in the prescription are added and subtracted aiming at the clinical symptoms of the pneumonia infected by the novel coronavirus.

Wherein the Maxingshigan decoction has the effects of ventilating lung and expelling pathogenic factors; the five-poria cocos disperses dampness-resolving and turbid-dispelling herbs, promotes the three-warmer and removes dampness from urine, so that the dampness is removed from pores and urine; minor bupleurum soup carding minor yang machine; the blackberry lily and ephedra decoction has the effects of relieving exterior syndrome, resolving fluid retention, depressing qi and relieving cough; the wrinkled gianthyssop herb, the immature bitter orange and the dried orange peel regulate qi activity of spleen and stomach, and move qi and dissolve turbidity with fragrance, so that turbid qi in chest and abdomen is removed and breath is smooth; in addition, yam can tonify spleen and kidney, and strengthen healthy qi. The whole formula has the effects of clearing damp and dissolving turbidity, clearing lung and expelling pathogenic factors and harmonizing qi activity.

Further preferably, the traditional Chinese medicine raw materials of the prescription consist of the following traditional Chinese medicine materials in parts by weight:

9 parts of ephedra, 6 parts of honey-fried licorice root, 9 parts of almond, 15-30 parts of gypsum, 9 parts of cassia twig, 9 parts of rhizoma alismatis, 9 parts of grifola, 9 parts of bighead atractylodes rhizome, 15 parts of poria cocos, 16 parts of radix bupleuri, 6 parts of scutellaria baicalensis, 9 parts of ginger processed pinellia tuber, 9 parts of ginger, 9 parts of aster, 9 parts of flos farae, 9 parts of blackberry lily, 6 parts of asarum, 12 parts of Chinese yam, 6 parts of immature bitter orange, 6 parts of dried orange peel and 9 parts of wrinkled gianthyssop herb.

Wherein the dosage of the gypsum is adjusted according to whether the patient has fever or not, if the patient does not have fever, the dosage of the gypsum is small, and if the patient has fever or high fever, the dosage of the gypsum is increased.

Furthermore, the formulation is a decoction.

In a second aspect, the invention provides a process for the preparation of said formulation: decocting the above materials with water, wherein Gypsum Fibrosum is decocted first, and then other Chinese medicinal materials (decoction pieces of Chinese medicinal materials) are added and decocted.

In a third aspect, the invention provides application of the prescription (lung-clearing and toxin-expelling decoction) in preparation of a medicine with a lung-clearing and toxin-expelling efficacy.

And the application of the prescription (lung-heat clearing and toxin expelling decoction) in preparing the medicine for treating the pneumonia diseases.

In particular, the pneumonia is pneumonia caused by a viral infection.

The viruses include, but are not limited to, novel coronavirus 2019-nCoV, respiratory syndrome coronavirus, and respiratory syncytial virus.

Objective experiments prove that the prescription disclosed by the invention has a good treatment effect on pneumonia caused by the infection of the novel coronavirus 2019-nCoV.

As a recommendation, the use method of the prescription is as follows: decoct the drugs with water, take them one dose a day, twice in the morning and at night (forty minutes after meal), and warm. If the condition is met, half bowl of rice soup is taken after each dose of the medicine, and more than one bowl of rice soup can be taken for patients with dry tongue and fluid deficiency. Three treatment courses are provided. The patients are advised to take the medicine for a treatment course according to the original prescription, and the patients take the medicine for a second treatment course if the symptoms are good and the patients are not cured. If the patient has special conditions or other basic diseases, the prescription can be modified according to the actual conditions in the second treatment course, and the medicine is stopped when the symptoms disappear.

In addition, if constipation occurs before taking the formula, Fangfeng Tongsheng Wan should be added, and the pill should be stopped after defecation is smooth.

The raw materials or reagents involved in the invention are all common commercial products, and the operations involved are all routine operations in the field unless otherwise specified.

The above-described preferred conditions may be combined with each other to obtain a specific embodiment, in accordance with common knowledge in the art.

The invention has the beneficial effects that:

the invention combines epidemic disease symptom expression of the novel coronavirus pneumonia, and considers that the pneumonia infected by the novel coronavirus (2019-nCoV) belongs to the field of cold plague in the traditional Chinese medicine, and dampness pathogen is exuberant. The primary location of the disease is in the lung, and the secondary location of the disease is in the exterior, defense, spleen and stomach; the main diseases are caused by the intermingled pathogenic factors of dryness and damp-cold. The main pathogenesis is the damp-cold of epidemic toxin and the accumulation of latent dryness, which causes the obstruction of qi movement and the abnormal ascending and descending.

The invention provides the prescription, and various traditional Chinese medicines are optimized and fused to be applied together. The curative effect is exact according to the current curing conditions of patients with confirmed diagnosis at different ages. Relevant clinical observations studies are ongoing.

The prescription (lung-clearing and toxin-expelling decoction) provided by the invention is used by the emergency scientific research special item of the State administration of traditional Chinese medicine, namely 'effective prescription clinical screening research on preventing and treating novel coronavirus infection in traditional Chinese medicine', clinical observation work is carried out by combining clinical treatment at present, and related research is continuously promoted. The prescription is suitable for light, common and heavy patients, can be reasonably used by combining the actual conditions of the patients in the treatment of the critically ill patients, and has good social benefits.

Detailed Description

Preferred embodiments of the present invention will be described in detail with reference to the following examples. It is to be understood that the following examples are given for illustrative purposes only and are not intended to limit the scope of the present invention. Various modifications and alterations of this invention will become apparent to those skilled in the art without departing from the spirit and scope of this invention.

The experimental procedures used in the following examples are all conventional procedures unless otherwise specified.

Materials, reagents and the like used in the following examples are commercially available unless otherwise specified.